Qureight, a deep-learning analytics company accelerating drug development through AI-powered data curation, today announced that its digitally-twinned synthetic control arm has been used in a breakthrough clinical trial application in place of a human placebo group, marking a world-first in lung disease research.
↧
Qureight's synthetic study arms validate clinical efficacy in pioneering rare lung disease treatment
↧